Literature DB >> 24953538

Informing women with breast cancer about endocrine therapy: effects on knowledge and adherence.

Sarah R Heisig1, Meike C Shedden-Mora, Pia von Blanckenburg, Franziska Schuricht, Winfried Rief, Ute-Susann Albert, Yvonne Nestoriuc.   

Abstract

OBJECTIVE: Adherence to adjuvant endocrine therapy in women with breast cancer is low, and patients are not informed sufficiently. This study analyzes the effects of a structured treatment information on patients' satisfaction, knowledge, and adherence.
METHODS: An interventional single cohort study of postoperative women with estrogen-receptor-positive breast cancer was conducted to study the effects of enhanced information about endocrine therapy given additionally to clinical routine information. Knowledge and satisfaction with additional information given 1-3 weeks after surgery were assessed before and after informing patients; adherence and knowledge were measured 3 months after start of treatment.
RESULTS: A total of 137 patients were analyzed before and after provision of enhanced treatment information as well as 3 months after start of endocrine therapy. Enhanced information increased satisfaction with information and knowledge. The percentage of patients who knew their estrogen receptor status increased from 50% to 93%. At 3 months follow-up, 60% still had correct knowledge. Patients who learned their receptor status were older, and those who forgot had lower cognitive abilities and lower educational level. Patients with higher satisfaction, better learning, and comprehension directly after enhanced information showed better adherence at 3 months follow-up.
CONCLUSION: Patients, especially older ones, can benefit from enhanced treatment information given additionally to routine care. Enhanced information about mode of action and potential side effects of endocrine therapy when included into clinical routine might foster patient autonomy and prevent early disruptions in adherence.
Copyright © 2014 John Wiley & Sons, Ltd.

Entities:  

Keywords:  adherence in oncology; adjuvant endocrine therapy; breast cancer; disease knowledge; treatment information

Mesh:

Substances:

Year:  2014        PMID: 24953538     DOI: 10.1002/pon.3611

Source DB:  PubMed          Journal:  Psychooncology        ISSN: 1057-9249            Impact factor:   3.894


  26 in total

1.  Deconstructing Decisions to Initiate, Maintain, or Discontinue Adjuvant Endocrine Therapy in Breast Cancer Survivors: A Mixed-Methods Study.

Authors:  Shirley M Bluethmann; Caitlin C Murphy; Jasmin A Tiro; Michelle A Mollica; Sally W Vernon; Leona Kay Bartholomew
Journal:  Oncol Nurs Forum       Date:  2017-05-01       Impact factor: 2.172

2.  Symptoms and Symptom Attribution Among Women on Endocrine Therapy for Breast Cancer.

Authors:  Shoshana M Rosenberg; Annette L Stanton; Keith J Petrie; Ann H Partridge
Journal:  Oncologist       Date:  2015-05-01

3.  Interventions to Enhance Adherence to Oral Antineoplastic Agents: A Scoping Review.

Authors:  Shoshana M Rosenberg; Keith J Petrie; Annette L Stanton; Lan Ngo; Emma Finnerty; Ann H Partridge
Journal:  J Natl Cancer Inst       Date:  2020-05-01       Impact factor: 13.506

4.  Racial differences in receipt of adjuvant hormonal therapy among Medicaid enrollees in South Carolina diagnosed with breast cancer.

Authors:  Tisha M Felder; D Phuong Do; Z Kevin Lu; Lincy S Lal; Sue P Heiney; Charles L Bennett
Journal:  Breast Cancer Res Treat       Date:  2016-04-27       Impact factor: 4.872

5.  Rural cancer survivors' health information needs post-treatment.

Authors:  Nynikka R Palmer; Nancy E Avis; Nora F Fino; Janet A Tooze; Kathryn E Weaver
Journal:  Patient Educ Couns       Date:  2020-02-27

6.  A systematic review of interventions to improve adherence to endocrine therapy.

Authors:  Sue P Heiney; Pearman D Parker; Tisha M Felder; Swann Arp Adams; Omonefe O Omofuma; Jennifer M Hulett
Journal:  Breast Cancer Res Treat       Date:  2018-11-01       Impact factor: 4.872

7.  Treatment Adherence and Its Impact on Disease-Free Survival in the Breast International Group 1-98 Trial of Tamoxifen and Letrozole, Alone and in Sequence.

Authors:  Jacquie H Chirgwin; Anita Giobbie-Hurder; Alan S Coates; Karen N Price; Bent Ejlertsen; Marc Debled; Richard D Gelber; Aron Goldhirsch; Ian Smith; Manuela Rabaglio; John F Forbes; Patrick Neven; István Láng; Marco Colleoni; Beat Thürlimann
Journal:  J Clin Oncol       Date:  2016-05-23       Impact factor: 44.544

8.  Racial and Geographic Disparities in Endocrine Therapy Adherence Among Younger Breast Cancer Survivors.

Authors:  Sue P Heiney; Samantha Truman; Oluwole A Babatunde; Tisha M Felder; Jan M Eberth; Elizabeth Crouch; Karen E Wickersham; Swann Arp Adams
Journal:  Am J Clin Oncol       Date:  2020-07       Impact factor: 2.787

9.  Study design and methods for the using exercise to relieve joint pain and improve AI adherence in older breast cancer survivors (REJOIN) trial.

Authors:  Shirley M Bluethmann; Cristina Truica; Heidi D Klepin; Nancy Olsen; Christopher Sciamanna; Vernon M Chinchilli; Kathryn H Schmitz
Journal:  J Geriatr Oncol       Date:  2021-05-26       Impact factor: 3.929

10.  Development and Refinement of a Telehealth Intervention for Symptom Management, Distress, and Adherence to Adjuvant Endocrine Therapy after Breast Cancer.

Authors:  Jamie M Jacobs; Emily A Walsh; Chelsea S Rapoport; Michael H Antoni; Elyse R Park; Kathryn Post; Amy Comander; Jeffrey Peppercorn; Steven A Safren; Jennifer S Temel; Joseph A Greer
Journal:  J Clin Psychol Med Settings       Date:  2020-11-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.